Serious Adverse Events - Section 1
If Yes, record details below. A serious adverse event is any untoward medical occurrence that, at any dose: a) results in death. b) is life-threatening: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. c) requires hospitalisation or prolongation of existing hospitalisation: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE. d) results in disability/incapacity: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption. e) is a congenital anomaly/birth defect. f) other. Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.
text
Ensure that no medical or investigational procedures are captured on Non-Serious Adverse Events pages. Death should not be recorded as an SAE but should be recorded as the outcome of an SAE. The condition that resulted in the death should be recorded as the SAE. Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE. However, if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page. If this was recorded previously as a non-serious event but has progressed to serious, put a line through the Non-Serious AE record and transcribe the details onto the SAE form.
text
Start dates must be provided for the reporting of adverse event data. If the exact date is not known, liaise with the investigator to ensure that a best estimate is provided.
date
Start Time Serious Adverse Event
time
Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = Those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).
text
All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death.
integer
Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s).
text
This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/ Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.
date
Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If the subject was withdrawn from the study due to an SAE, confirm that the following variables are consistent for the adverse event which resulted in withdrawal: If investigational product was permanently withdrawn due to an adverse event: ‘Primary Reason for Withdrawal’ on the Study Conclusion page is recorded as ‘Adverse Event’ If the subject was withdrawn from the study for an adverse event: ‘Withdrawal’ on the Serious Adverse Events page is recorded as ‘Yes’, ‘Action Taken with Investigational Product(s) as a Result of the SAE’ on the Non-Serious Adverse Events page is recorded as ‘Investigational Product Withdrawn’.
text
End Time Serious Adverse Event
time
It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.
text
Intermittent should be used if the subject experiences the same AE on multiple occasions over a period of time (e.g., dizziness). In these circumstances, the start date will be the start date of the first episode and the end date will be the date of resolution.
integer
If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.
text
Serious Adverse Events - Section 2: Seriousness
Serious Adverse Event resulting in Death
boolean
Life-threatening Serious Adverse Event
boolean
Serious Adverse Event requiring hospitalisation (prolongation)
boolean
Serious adverse event resulting in disability
boolean
Serious Adverse Event: congenital anomaly/birth defect
boolean
Serious Adverse Event, other reason for seriousness
boolean
Serious Adverse Event, other reason for seriousness
text
Serious Adverse Events - Section 3: Demography Data
Serious Adverse Events - Section 4: Recurrence
If deliberate or inadvertent administration of further dose(s) of investigational product(s) to the subject occurred, did the reported adverse event recur?
text
Serious Adverse Events - Section 5: Possible Causes Of SAE Other Than Investigational Products
Cause of Serious Adverse Event: Disease under Study
boolean
Cause of Serious Adverse Event: Medical Condition
boolean
Cause of Serious Adverse Event: Medical Condition
text
Cause of Serious Adverse Event: Lack of Efficacy
boolean
Cause of Serious Adverse Event: Withdrawal of Investigational Products
boolean
Cause of Serious Adverse Event: Concomitant Medications
boolean
Cause of Serious Adverse Event: Concomitant Medications
text
Cause of Serious Adverse Event: Activity related to study participation (e.g., procedures)
boolean
Other Cause of Serious Adverse Event
boolean
Other Cause of Serious Adverse Event
text
Serious Adverse Events - Section 6: Relevant medical conditions
Serious Adverse Event: Medical Disorder, Allergy, Surgery
text
Date of Onset
date
Present at Serious Adverse Event
text
Date of last occurence
date
Serious Adverse Events - Section 7: Other relevant risk factors
Serious Adverse Events - Section 8: Relevant concomitant medication
Include details of any concomitant medication(s) which may have contributed to the event. Trade name preferred.
text
Dose
float
Unit
text
Frequency
text
Route
text
Taken prior to study?
text
Start Date
date
Stop Date
date
Ongoing medication?
text
Reason for medication
text
Serious Adverse Events - Section 9: Details of investigational Products
Complete this section using the information in the Investigational Product page. Details of all investigational product(s) taken until the time of the SAE should be included. Provide specific details in Section 11 Narrative Remarks if the subject has taken an overdose of investigational product(s), including whether it was accidental or intentional.
text
Treatment blind broken
text
SECTION 10: Details of RELEVANT Assessments
Serious Adverse Events - Section 11: Narrative Remarks
Narrative Remarks
text
confirming that the data on the SAE pages are accurate and complete
text
Date of Investigator signature
date
Investigator's Name
text